We are international
Donate
TEXT SIZE   


Myeloma Minute - January 23, 2007
01.23.07
WHAT'S NEWS

Happy 2007! The Minute is back and we are raring to go. This promises to be a stellar year for myeloma research and support. And the Minute will be there to keep you up to date. So, shake off the old and welcome to the new!


We couldn't take you with us to the American Society of Hematology (ASH) Meeting in Orlando, Florida, so we did the next best thing.
We brought the meeting to you!

Webcasts
We interviewed fifty of the top researchers in the field of myeloma. We asked them to explain their research in language we could all understand, and they did. They talked about new agents, and new combinations of novel agents, and we brought that information back with us to share with you. In plain English...and Spanish...and French...and German...and Italian...and Hebrew...and Turkish...and Czech.

Support Group Leader Reports
We didn't go alone to Orlando. We took 15 Support Group Leaders with us to get their take on one of the biggest meetings of the year.
2007 Brian D. Novis Grant Winners Announced at ASH
The recipients of the 2007 IMF Research Grant awards were announced at the gathering of the Foundation’s Scientific Advisors.

David Smith Named Executive Director of the IMF
David previously served as the vice president of operations. As executive director, his new responsibilities will encompass an expanded management role that oversees much of the day-to-day operations of the foundation as well as many key programs that serve the varied constituencies of the IMF.


FDA Accepts Ortho Biotech's sNDA for DOXIL® in Combination with VELCADE® to Treat Relapsed/Refractory Multiple Myeloma
The Supplemental New Drug Application (sNDA) is based on a planned interim analysis from the DOXIL-MMY-3001 trial, an international, multicenter, phase 3, randomized, open-label study of 646 patients with relapsed or refractory multiple myeloma who had received at least one prior line of therapy, and who were randomized to receive the DOXIL + VELCADE combination or VELCADE alone. (from Yahoo Finance)

Time to Act!
If you have been thinking about registering for the IMF's Los Angeles Patient & Family Seminar, which hits town on
February 23-24, 2007, you need to put thought into action! The seminar is filling up fast, and with presentations such as "Managing Side Effects," "How to be a Better Patient," and the future of myeloma treatment in "Emerging Therapies," this promises to be a great event. Don't wait. Register now!

ASCO names top advances of 2006
The Editorial Board of the American Society of Clinical Oncology published its second annual list of the year's most important research findings, along with recommendations for getting more bang out of each cancer research buck. They noted that recent discoveries in the field of targeted therapies promise to change the way patients with certain types of cancer are treated -- and improve their outlook. (from Yahoo News )


The International Myeloma Foundation Unveils Plans for MYELOMA MOBILE to Travel Across the U.S. This Summer
The MYELOMA MOBILE is the brainchild of Michael Tuohy of Prospect, CT, who was diagnosed with myeloma when he was just 36 years old. Michael will be traveling with his wife, Robin, and their two children, 14-year-old Ally and 9-year-old Mikey.


Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA™ in Breakthrough Pain
Data from the first Phase 3 clinical trial to demonstrate positive results of FENTORA (fentanyl buccal tablet)
in opioid-tolerant patients with neuropathic pain. Onset of pain relief began in 10 minutes in this study as well as in a separate Phase 3 study in opioid- tolerant patients with cancer. (from Cephalon)

Apply NOW to NCI's All-Consumer Advisory Committee!
The National Cancer Institute's Office of Liaison Activities (OLA) invites all interested and eligible advocates, consumers and survivors to apply for 4 vacancies on the NCI Director's Consumer Liaison Group (DCLG), with terms beginning July, 2007. The DCLG is a Federal Advisory Committee of 16 cancer advocates and consumer members who are appointed by the Director of NCI. DCLG members provide broad-based recommendations to the NCI Director, and serve as a forum to receive feedback and input from all areas of the cancer advocacy community. The NCI Director has identified eliminating cancer disparities and research issues in cancer care delivery as two focus areas for the DCLG in 2007. Applications must be postmarked by March 30, 2007.


IMF PSA screened at NATPE 2007 in tribute to former head of membership Brigette Parise
Thanks to the involvement of Women In Film Los Angeles' PSA Production Program, NATPE screened the International Myeloma Foundation public service announcement resulting from NATPE's 2005 Brigette Parise Public Service Announcement Initiative. The initiative honors the memory of NATPE's former head of membership Brigette Parise, who died as a result of multiple myeloma.


The Fifth Myeloma Quilt of Courage has been completed!
This is the last of the series, and is an inspiration to all of us in the myeloma community. Many thanks to
Harriet Bertsche for heading this project up.

House, defying veto threat, passes bill on government bargaining for Medicare drug prices
The House drug legislation directs the secretary of Health and Human Services to bargain directly with drug companies, altering a fundamental provision of the 2003 law that created the Medicare drug benefit for seniors. (from Yahoo News)


Cents for Cells Raises Hopes
Beth Morgan has a purplish scar on her neck where a catheter was used to extract stem cells. The procedure gave Morgan an idea for a fundraiser. She launched "Cents for Cells" in an effort to raise a penny for each stem cell she saved—15 million in all. But the goal is to collect at least $50,000 for the International Myeloma Foundation to help others suffering from myeloma. So far, she has raised about $3,000. (from the Fayetteville Observer)
Click here to donate to Cents for Cells.

Firefighters face higher cancer rates
A study released by the University of Cincinnati has determined that firefighters are at a greater risk of developing myeloma and three other different types of cancer than the general population — and also suggests the protective equipment firefighters are using is insufficient in protecting them against cancer-causing agents. (from The Stamford Times)


Turn Your Vacations Into Donations!
We are excited to introduce you to our first edition of the IMF Travel Advantage newsletter. As part of our travel program, every two weeks we will bring to you some of the best travel deals on the internet through a special newsletter supplement created especially for IMF supporters and friends.

WHAT'S NEW IN RESEARCH
ARTICLES
(IMF Scientific Advisors are marked with an *)
  • Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
    Herve Avet-Loiseau*, Michel Attal*, Philippe Moreau, Catherine Charbonnel, Frederic Garban, Cyrille Hulin, Serge Leyvraz, Mauricette Michallet, Ibrahim Yakoub-Agha, Laurent Garderet, Gerald Marit, Lucienne Michaux, Laurent Voillat, Marc Renaud, Bernard Grosbois, Gaelle Guillerm, Lotfi Benboubker, Mathieu Monconduit, Catherine Thieblemont, Philippe Casassus, Denis Caillot, Anne-Marie Stoppa, Jean-Jacques Sotto, Marc Wetterwald, Charles Dumontet, Jean-Gabriel Fuzibet, Isabelle Azais, Veronique Dorvaux, Marc Zandecki, Regis Bataille*, Stephane Minvielle, Jean-Luc Harousseau*, Thierry Facon, and Claire Mathiot
    Blood published 5 January 2007, 10.1182/blood-2006-08-040410

CLINICAL TRIALS
  • VELCADE® trials

  • THALOMID® trials

  • REVLIMID® trials

  • DOXIL® trials

  • Phase I-II clinical trial of high-dose intravenous vitamin C as a treatment for cancer patients who have incurable cancer that has failed, or is inappropriate for, standard therapies. Clinical Research Unit, McGill University, Montreal, Canada. Sponsored by the National Cancer Institute of Canada and open only to Canadian citizens.
  • NEW TO THE MATRIX
    • Preclinical
      Name: AMG523
      Sponsor: Amgen
      Indication: B-cell activating factor (BAFF) inhibitor active in MM cell lines

    • Preclinical
      Name: AZD6244 (ARRY-142886)
      Sponsor: Astra Zeneca
      Indication: MEK 1/2 inhibitor which inhibits the proliferation and survival of human MM cell lines.

    • Preclinical
      Name: HuLuc63
      Sponsor: PDL Biopharma, Inc & Dana-Farber
      Indication: novel humanized monoclonal antibody to CS1, a myeloma antigen expressed in more than 96% of mm patients.

    • Preclinical
      Name: Reversine (2-(4-Morpholinoanilino)-6-cyclohexylaminopurine)
      Sponsor: Dana-Farber Cancer Institute
      Indication: small molecule that may represent a distinct class of agents with therapeutic potential for specific subsets of MM.

    • Preclinical
      Name: SF1126
      Sponsor: Semafore
      Indication: novel RGD targeted derivative of LY294002 with significant antiangiogenic activity in MM cells.

    • Preclinical
      Name: VE465
      Sponsor: Vertex/Merck
      Indication: Aurora kinase inhibitor that is active in vitro against MM cell lines and/or primary MM tumor cells resistant to various anti-myeloma therapies.

If you would like more information about any clinical trial, you can call the IMF Hotline at 800-452-CURE. The Myeloma Matrix has a current list of all myeloma trials from pre-clinical to recently FDA approved. If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find EmergingMed, with whom the IMF has entered into a partnership to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute.

UPCOMING SEMINARS AND CLINICAL CONFERENCES
Los Angeles Patient & Family Seminar
February 23-24, 2007
Los Angeles, California
Houston Patient & Family Seminar
March 23-24, 2007
Houston, Texas
Teaneck Patient & Family Seminar
July 27-28, 2007
Teaneck, New Jersey

UPCOMING EVENTS

The IMF's comprehensive "How-to-FUNdraise" guide is what you need if you're thinking about fundraising in your community but don't know where to start. The guide contains the A - Z of fundraising ideas--like running in a local marathon and asking for donations per mile for myeloma; having a holiday party, where you charge a cover and hold a raffle; asking your local supermarket to donate wine and cheese, then selling tickets and having a cocktail party--as well as tips and guidelines for success. Check out the FUNdraisers below and show your support by donating to their effort online:

Cents for Cells
Beth Morgan is about to undergo a stem cell transplant and she is asking family and friends to help her help the IMF by raising a penny for each stem cell that will be collected. She has dedicated Cents for Cells to the memory of Chris Hollyer.
The Stratford Runner
Sheldon is running 1000 kilometers across Canada to raise money to support myeloma research.

Yard Sale
January 27, 2007
Jacksonville, Florida

Sheridan-Shedenhelm Wedding
February 3, 2007
Tampa, Florida

Molnar Marathon
April 28, 2007
Louisville, Kentucky

8th Annual JC Golf Tournament
May 19, 2007
Saint Cloud, Minnesota


HELPING THE IMF
If you use the special IMF links to shop at your favorite internet retailers (e-tailers) like Amazon.com, they will donate a portion of your purchase to the IMF. You pay no more than you would normally for everything from clothing to computers to cruises. Whatever you buy, the programs, publications and research supported by the IMF will benefit. Visit our Shop for the IMF page at http://shop.myeloma.org to see the complete list of popular etailers who will donate a portion of your purchase to the IMF. Giving has never been more painless!
The Gift of Hope
IMFers are requesting Mail For The Cure envelopes and letter templates to include in their Holiday cards this year. What better way to let your friends and family know how they can give the gift of hope at this time of year? Please contact Suzanne Battaglia at SBattaglia@myeloma.org or (800) 452-CURE (2873) and let her know how many envelopes you need. And don't forget to order the IMF's Holiday Ornament ($10 each).
Calling All Kids!
If you are ready to fight back against myeloma, then you need Kids Fight Back, a fundraising program especially for kids.
Tribute Cards
Order these beautiful tribute cards to send out to your friends and family every time you make a donation in their honor to the IMF.
Recipes for Research
Marilyn Alexander, the Philadelphia support group, and the IMF community have come together to create one terrific cookbook and handy kitchen reference. From Autumn Apple Cake to Veal Stimbarada, there is something here for every taste. And if you aren't in the mood to cook tonight, there is an entire section with tips on everything from setting the table to stain remover. At only $15, it will make a great holiday gift.
Imagine Moving Forward is the theme of the IMF's popular myeloma bracelet. At medical conferences and patient & family seminars we see people wearing them in honor, celebration, or in memory of a loved one. They're only $1 each in sets of 10, so order them for everyone you know who has been touched by myeloma. Order them on the web. If you have questions about the bracelets or would like more information, contact Suzanne Battaglia at (800) 452-2873, ext. 227, or SBattaglia@myeloma.org.
See more exciting ways to help the IMF continue its important work in education, support and research.

ITEMS OF INTEREST
New Help for Underinsured Myeloma Patients
Thanks to the advocacy of the IMF, the Chronic Disease Fund has received an infusion of new money to help them meet the needs of underinsured patients with multiple myeloma. The fund is designed to help patients with their insurance co-payments and/or their Medicare Part D 'doughnut holes.' Patients must qualify based on financial need. To speak with a representative of the Chronic Disease Fund, please call 877-968-7233, or contact them through their web site at cdfund.org.

Mensajero del Mieloma
La IMF quiere enviar información sobre el mieloma en español a todos los pacientes, familiares e interesados. Para suscribirse al correo electrónico (enviaremos diez números al año), por favor, envíe su dirección a mensajero@myeloma.org. ¡Gracias!


BANK ON A CURE®

International Staging System

NexProfiler
A tool to help understand the current status of the disease and the questions you should be asking.

HealthTalk's Multiple Myeloma Education Network
Please call the hotline (800) 452-CURE (800-452-2873) or email TheIMF@myeloma.org if you have any questions.
Copyright 2002-2007. International Myeloma Foundation. All Rights Reserved.


 related articles